SynthesisPsychopharmacology2008
Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis.
Synthesis in Psychopharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Pooled it
- Vortioxetine for depression in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study.BMJ (Clinical research ed.) · 2015Pooled it
- A systematic review of Chinese randomized clinical trials of SSRI treatment of depression.BMC psychiatry · 2014Pooled it
- Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity.European archives of psychiatry and clinical neuroscience · 2009Pooled it
- Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.Molecular psychiatry · 2020Trial
- Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine.Psychopharmacology · 2022Review
- Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States.Psychiatric services (Washington, D.C.) · 2020Article
- The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model.Annals of internal medicine · 2019Article
- Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States.JAMA psychiatry · 2018Article
- How should primary care doctors select which antidepressants to administer?Current psychiatry reports · 2012Review
- Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions.International journal of legal medicine · 2011Article
- SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2011Article
- Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study.The primary care companion for CNS disorders · 2011Article
- Desvenlafaxine in the treatment of major depressive disorder.Neuropsychiatric disease and treatment · 2009Article
- The review by Weinmann and colleagues.Psychopharmacology · 2008Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleA number of reviews have claimed that the selective serotonin and noradrenalin re-uptake inhibitor venlafaxine is more effective than selective serotonin re-uptake inhibitors (SSRIs) in achieving remission and symptom reduction in major depression.
objectivesThe aim of this study was to systematically review studies on the efficacy of venlafaxine vs SSRI and to evaluate the influence of methodological issues on the effect sizes. MATERIALS AND
methodsFollowing a systematic literature search, we pooled data on depression scores, response, remission and dropout rates. We also performed sub-group analyses.
resultsSeventeen studies were included. We found no significant superiority in remission rates (risk ratio [RR] = 1.07, 95% confidence intervals [95%CI] = 0.99 to 1.15, numbers needed to treat [NNT] = 34) and a small superiority in response rates (RR = 1.06, 95%CI = 1.01 to 1.12, NNT = 27) over SSRIs. There was a small advantage to venlafaxine in change scores (effect size = -0.09, 95%CI = -0.16 to -0.02, p = 0.013), which did not reach significance when post-treatment scores were used (effect size = -0.06, 95%CI = -0.13 to 0.00). Discontinuation rates due to adverse events were 45% higher in the venlafaxine group. The main reasons for the differences between this analysis and previous reviews were the exclusion of studies with methodological limitations, avoiding to pool selectively reported study results and exclusion of studies available as abstracts only.
conclusionsOur analysis does not support a clinically significant superiority of venlafaxine over SSRIs. Differences between our study and previous reviews were not accounted for by technical aspects of data synthesis, but rather by study selection and choice of outcome parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.